Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).

• 影响指数: 3.674
• 发表时间: Aug 2020
• 来源期刊: Eur J Haematol
• DOI: 10.1111/ejh.13423
• PMID: 32277501
• 文章类型: Journal Article
• 中科院分区: Q3
• 方向: 医学
• 作者列表: Jeanpierre E,Pouplard C,Lasne D,Le Cam Duchez V,Eschwege V,Flaujac C,Galinat H,Harzallah I,Proulle V,Smahi M,Sobas F,Stepina N,Toulon P,Voisin S,Ternisien C,Nougier C,

关键词: Factor IX; Factor VIII; chronometric and chromogenic assays; haemophilia A; haemophilia B

Mesh: Blood Coagulation; Blood Coagulation Tests / methods; Clinical Decision-Making; Disease Management; Drug Monitoring; Factor IX / administration & dosage pharmacokinetics; Factor VIII / administration & dosage pharmacokinetics; Hemophilia A / blood diagnosis drug therapy; Hemophilia B / blood diagnosis drug therapy; Humans; Recombinant Proteins / administration & dosage pharmacokinetics; Treatment Outcome

Abstract

Replacement therapy with plasma-derived or recombinant FVIII and FIX (pdFVIII/pdFIX or rFVIII/rFIX) concentrates is the standard of treatment in patients with haemophilia A and B, respectively. Measurement of factor VIII (FVIII:C) or factor IX (FIX:C) levels can be done by one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). The French study group on the Biology of Hemorrhagic Diseases (a collaborative group of the GFHT and MHEMO network) presents a literature review and proposals for the monitoring of FVIII:C and FIX:C levels in treated haemophilia A and B patients, respectively. The use of CSA is recommended for the monitoring of patients treated with pdFVIII or rFVIII including extended half-life (EHL) rFVIII. Except for rFVIII-Fc, great caution is required when measuring FVIII:C levels by OSA in patients substituted by EHL-rFVIII. The OSA is recommended for the monitoring of patients treated with pdFIX or rFIX. Large discordances in the FIX:C levels measured for extended half-life rFIX (EHL-rFIX), depending on the method and reagents used, must lead to great attention when OSA is used for measuring FIX:C levels in patients substituted by EHL-rFIX. Data of most of recent studies, obtained with spiked plasmas, deserve to be confirmed in plasma samples of treated patients.